Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

128.44 +2.53 (+2.01%)
Official Closing Price Updated: 4:10 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,557,580
Open 126.52
Bid (Size) 128.07 (1)
Ask (Size) 128.87 (1)
Prev. Close 125.91
Today's Range 126.08 - 128.88
52wk Range 119.59 - 148.62
Shares Outstanding 122,180,759
Dividend Yield 2.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Balancing Dividends and Fundamentals: The Case of NYSE:DGX.
Uncovering Dividend Opportunities with QUEST DIAGNOSTICS INC (NYSE:DGX). 
Via Chartmill
Key Takeaways From Quest Diagnostics Analyst Ratings
Via Benzinga

Performance

YTD
-8.79%
-8.79%
1 Month
-0.48%
-0.48%
3 Month
-4.31%
-4.31%
6 Month
+4.57%
+4.57%
1 Year
-10.53%
-10.53%

More News

Read More
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Via Chartmill
LifeMD Shares Come Back to Life on GLP-1 Business Growth
Via MarketBeat
AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow
Via Benzinga
Topics Bonds
Exposures Debt Markets
(DGX) - Analyzing Quest Diagnostics's Short Interest
Via Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Via Chartmill
Breaking Down Quest Diagnostics: 7 Analysts Share Their Views
Via Benzinga
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Is NYSE:DGX suited for dividend investing?
Via Chartmill
Beyond The Numbers: 7 Analysts Discuss Quest Diagnostics Stock
Via Benzinga
Investor Sentiment Falls Sharply Following Fed's Rate Decision; Dow Dips Over 300 Points
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Earnings Outlook For Quest Diagnostics
Via Benzinga
Expert Ratings for Quest Diagnostics
Via Benzinga
Earnings Scheduled For February 1, 2024
Via Benzinga
The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market
Via InvestorPlace
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
Via Benzinga
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
From Ultima Genomics
Via Business Wire
Consulting Firm McKinsey Concludes Opioid Litigation Settlement With $78M Agreement
Via Benzinga
Quest Diagnostics Gains Momentum: Analyst Highlights Strong Business Trends And Growth Opportunities
Via Benzinga
Supreme Court Set to Decide Future of Mifepristone: Showdown Looms Over FDA's Endorsement
Via Benzinga
Exposures Product Safety
Quest Diagnostics Inc. (NYSE: DGX) Highlighted for Surprising Price Action
Via Investor Brand Network
Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.